Empfehlungen zur kalkulierten parenteralen Initialtherapie ...

Klaus-Friedrich Bodmann, Béatrice Grabein und die Expertenkommission der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V.
34. Kuang D, Verbine A, Ronco C. Pharmacokinetics
and antimicrobial dosing
adjustment in critically ill patient during
continous renal replacement therapy.
Clin Nephrol 2007;67:267-384.
35. Kuti JL, Dandekar PK, Nightingale
CH, Nicolau DP. Use of Monte
Carlo simulation to design an optimized
pharmacodynamic dosing strategy
for meropenem. J Clin Pharmacol
2003;43:1116-23.
36. Kuti JL, Nightingale CH, Knauft RF,
Nicolau DP. Pharmacokinetic properties
and stability of continuous-infusion
meropenem in adults with cystic fibrosis.
Clin Ther 2004;26:493-501.
37. Kuzenko J, Crawford C. Continuous
infusion of ceftazidime in cystic fibrosis.
Lancet 1989;11:385.
38. Landersdorfer CB, Kirkpatrick CMJ,
Kinzig-Schippers M, Bulitta JB, et al.
Population pharmacokinetics at two
dose levels and pharmacodynamic
profiling of flucloxacillin. Antimicrob
Agents Chemother 2007;51:3290-7.
39. Lau W, Mercer D, Itani K, Nicolau D,
et al. A randomized, open-label, comparative
study of piperacillin/tazobactam
administered by continuous infusion vs.
intermittent infusion for the treatment
of hospitalized patients with complicated
intra-abdominal infection. Antimicrob
Agents Chemother 2006;50:3556-
61.
40. Lavole GY, Bergeron MG. Influence
of four modes of administration on
penetration of aztreonam, cefuroxime,
and ampicillin into interstitial
fluid and fibrin clots and on invivo
efficacy against Haemophilus influenzae.
Antimicrob Agents Chemother
1985;28:404-12.
41. Lee BL, Sachdeva M, Chambers HF.
Effect of protein binding of daptomycin
on MIC and antibacterial activity.
Antimicrob Agents Chemother
1991;35:2505-8.
42. Llopis-Salvia P, Jiménez-Torres NV.
Population pharmacokinetic parameters
of vancomycin in critically ill patients.
J Clin Pharm Ther 2006;31:447-54.
43. Lorente L, Lorenzo L, Martin MM, Jimenez
A, et al. Meropenem by continuous
versus intermittent infusion in ventilator-associated
pneumonia due to Gramnegative
bacilli. Am Pharmacother
2006;40:219-23.
44. Lortholary O, Lefort A, Tod M, Chomat
AM, et al. Pharmacodynamics and pharmacokinetics
of antibacterial drugs in
the management of febrile neutropenia.
Lancet Infect Dis 2008;8:612-20.
45. MacGowan AP. Pharmacodynamics,
pharmacokinetics, and therapeutic drug
monitoring of glycopeptides. Ther Drug
Monit 1998;20:473-7.
26
46. Moore RD, Lietman PS, Smith CR. Clinical
response to aminoglycoside therapy:
importance of the ratio of peak concentration
to minimal inhibitory concentration.
J Infect Dis 1987;155:93-9.
47. Mouton JW, Horrevorts AM, Mulder
PGH, Prens EP, et al. Pharmacokinetics
of ceftazidime in serum and suction
blister fluid during continuous and
intermittent infusions in healthy volunteers.
Antimicrob Agents Chemother
1990;34:2307-11.
48. Mouton JW, Michel MF. Pharma coki netics
of meropenem in serum and suction
blister fluid during continuous and intermittent
infusion. J Antimicrob Chemother
1991;28:911-8.
49. Mouton JW, Vinks AATMM, Punt NC.
Pharmacokinetic-pharmacodynamic
modeling of activity of ceftazidime
during continuous and intermittent
infusion. Antimicrob Agents Chemother
1997;41:733-8.
50. Munckhof WJ, Carney J, Neilson G,
Neilson J, et al. Continuous infusion of
ticarcillin-clavulanate for home treatment
of serious infections: clinical
efficacy, safety, pharmacokinetics and
pharmacodynamics. Int J Antimicrob
Agents 2005;25:514-22.
51. Nath SK, Foster GA, Mandell LA, Rotstein
C. Antimicrobial activity of ceftriaxone
versus cefotaxime: negative
effect of serum albumin binding of
ceftriaxone. J Antimicrob Chemother
1994;33:1239-43.
52. Neftel KA, Walti M, Schulthess HK,
Gubler J. Adverse reactions following
intravenous penicillin-G relate to
degradation of the drug in vitro.
Klin Wochenschr 1984;62:25-9.
53. Neftel KA, Walti M, Spengler H, von
Felton A, et al. Neutropenia after
penicillins: toxic or immune-mediated?
Klin Wochenschr 1981;59:877-8.
54. Neftel KA. Effect of storage of penicillin-
G solutions on sensitization to penicillin-
G after intravenous administration.
Lancet 1982;986-8.
55. Newman D, Scheetz MH, Adeyemi OA,
Montevecchi M, et al. Serum piperacillin/tazobactam
pharmacokinetics in a
morbidly obese individual. Ann Pharmacother
2007;41:1734-9.
56. Nicolau DP, Lacy MK, McNabb J, Quintiliani
R, et al. Pharmacokinetics of continuous
and intermittent ceftazidime in
intensive care unit patients with nosocomial
pneumonia. Infect Dis Clin Pract
1999;8:45-9.
57. Nicolau DP, McNabb JC, Lacy MK,
Quintiliani R, et al. Continuous versus
intermittent administration of ceftazidime
in intensive care unit patients with
nosocomial pneumonia. Int J Antimicrob
Agent 2001;17:497-504.
58. Nicolau DP. Pharmacodynamic optimization
of beta-lactams in the patient care
setting. Crit Care 2008;12(Suppl 4):2.
59. Olsen KM, Rudis MI, Rebuck JA, Hara
J, et al. Effect of once-daily dosing vs.
multiple daily dosing of tobramycin on
enzyme markers of nephrotoxicity. Crit
Care Med 2004,32:1678-82.
60. Pai MP, Bearden DT. Antimicrobial
do sing considerations in obese adult
patients. Pharmacotherapy 2007;27:
1081-91.
61. Pea F, Furlanut M, Negri C, Pavan F, et
al. Prospectively validated dosing nomograms
for maximizing the pharmacodynamics
of vancomycin administered by
continuous infusion in critically ill patients.
Antimicrob Agents Chemother
2009;53:1863-7.
62. Pea F, Viale P. Bench-to-bedside review:
Appropriate antibiotic therapy in severe
sepsis and septic shock--does the dose
matter? Crit Care 2009;13:214.
63. Rea RS, Capitano B, Bies R, Bigos KL, et
al. Suboptimal aminoglycoside dosing
in critically ill patients. Ther Drug Monit
2008;30:674-81.
64. Reese AM, Frei CR, Burgess DS. Pharmacodynamics
of intermittent and continuous
infusion piperacillin/tazobactam
and cefepime against extendedspectrum
beta-lactamase-producing
organisms. Int J Antimicrob Agents
2005;26:114-9.
65. Roberts JA, Lipman J. Antibacterial
dosing in intensive care: pharmacokinetics,
degree of disease and pharmacodynamics
of sepsis. Clin Pharmacokinet
2006;45:756-73.
66. Roberts JA, Lipman J. Pharmacokinetic
issues for antibiotics in the critically ill
patient. Crit Care Med 2009;37:840-51.
67. Roberts JA, Lipman J.Optimizing use
of beta-lactam antibiotics in the critically
ill. Semin. Respir Crit Care Med
2007;28:579-85.
68. Roberts JA, Paratz J, Paratz E, Krueger
WA, et al. Continuous infusion of betalactam
antibiotics in severe infections:
a review of its role. Int J Antimicrobial
Agents 2007;30:11-8.
69. Roberts JA, Roberts MS, Robertson TA,
Dalley AJ, et al. Piperacillin penetration
into tissue of critically ill patients
with sepsis-bolus versus continuous
administration. Crit Care Med 2009;37:
926-33.
70. Scaglione F, Paraboni L. Pharmacokinetics/pharmacodynamics
of antibacterials
in the Intensive Care Unit: setting
appropriate dosing regimens. Int J Antimicrobial
Agents 2008;32:294-301.
71. Scaglione F, Raichi M, Fraschini F. Serum
protein binding and extravascular diffusion
of methoxyimino cephalosporins.
Time courses of free and total concentrations
of cefotaxime and ceftriaxone
in serum and pleural exudates. J Antimicrob
Chemother 1990;26 (Suppl A):1-
10.